OVARIAN CLEAR CELL ADENOCARCINOMA
Clinical trials for OVARIAN CLEAR CELL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new OVARIAN CLEAR CELL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for OVARIAN CLEAR CELL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Less invasive surgery may help ovarian cancer patients recover faster
Disease control Recruiting nowThis study tests if a less invasive surgery (laparoscopy) works as well as standard open surgery for people with advanced ovarian, fallopian tube, or peritoneal cancer who have already had chemotherapy. About 580 participants will be randomly assigned to one of the two surgeries.…
Matched conditions: OVARIAN CLEAR CELL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 11:48 UTC
-
New combo therapy aims to drain ovarian Cancer's fluid trap
Disease control Recruiting nowThis study tests whether adding an experimental drug (APL-2) to standard immunotherapy (pembrolizumab) and a targeted therapy (bevacizumab) works better than bevacizumab alone for recurrent ovarian, fallopian tube, or peritoneal cancer that causes fluid buildup. About 60 adults w…
Matched conditions: OVARIAN CLEAR CELL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 26, 2026 11:45 UTC
-
New drug cocktail aims to shrink ovarian tumors in recurrent cancer
Disease control Recruiting nowThis study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy combo (pembrolizumab and bevacizumab) can shrink tumors in people with ovarian cancer that has returned. About 80 adults with recurrent ovarian, fallopian tube, or peritoneal cancer will r…
Matched conditions: OVARIAN CLEAR CELL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 26, 2026 11:45 UTC
-
New drug combo targets Hard-to-Treat ovarian and endometrial cancers
Disease control Recruiting nowThis early-phase study tests two experimental drugs (M1774 and ZEN-3694) together in people whose ovarian or endometrial cancer has returned. The goal is to find the safest dose and see how well the combination works. About 65 participants will take part to help determine if this…
Matched conditions: OVARIAN CLEAR CELL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:04 UTC